
Earth's CO2 hits highest recorded level in human history, experts say
The more CO2 in the atmosphere, the higher the rate of global warming , which could one day could make Earth's surface too hot for humans. At much higher concentrations, CO2 can also cause a variety of health issues. Worryingly, this includes cognitive impairment, drowsiness, nausea and even death in the most extreme cases. 'Another year, another record,' said Ralph Keeling, director of the Scripps CO2 Program.
He added: 'It's sad.' Like other greenhouse gases, CO2 acts like a blanket, trapping heat and warming the lower atmosphere. This changes weather patterns and fuels extreme events, such as heat waves, droughts, wildfires, heavy rain and flooding. Rising CO2 levels also contribute to ocean acidification , which makes it more difficult for marine organisms like crustaceans and coral to grow hard skeletons or shells.
The experts' new measurements come from Mauna Loa Observatory, a research station situated high on the slopes of the Mauna Loa volcano, Hawaii. At 11,141 feet above sea level, Mauna Loa Observatory measures different gases in the air by shining different kinds of light and radiation through air samples. According to the experts, the observatory's monthly average for May 2025 of 430.2 ppm is an increase of 3.5 ppm over May 2024's measurement of 426.7 ppm. Meanwhile, NOAA's Global Monitoring Laboratory in Boulder, Colorado has separately reported an average of 430.5 ppm – an increase of 3.6 ppm over last year.
In a post on X , Jeff Berardelli, meteorologist and climate specialist for WFLA Tampa Bay, called the new record 'concerning'. CO2 is by far the most abundant human-caused greenhouse gas and it can persist in the atmosphere and oceans for thousands of years. According to scientists, the amount of carbon present now in the Earth's atmosphere is equal to that which would have been seen some 4.1 to 4.5 million years ago, during a time which scientists refer to as the 'Pliocene Climatic Optimum'.
At this time, the sea level was a whopping 78 feet (24 meters) higher than in the present day, while the average global temperature stood at 7°F (3.9°C) higher than it was before the Industrial Revolution. In fact, the temperature was so warm during this period of time that large forests occupied areas of the Arctic which today are barren, chilly tundra. Although humanity is constantly pumping out CO2 all-year-round, atmospheric CO2 is at its highest in the Northern Hemisphere in the spring – specifically May.
Between autumn and spring, much of the hemisphere's plant matter decomposes, releasing CO2 into the atmosphere as it does so. May tends to represent the highest extend of atmospheric CO2 before plants come to life and draw in CO2 to fuel their growth. This begins the process of lowering the amount of CO2 in the atmosphere until the autumn when the plants start to die – and the cycle continues. Researchers say Mauna Loa Observatory's new measurements represent the average state of CO2 in the atmosphere of the Northern Hemisphere.
However, CO2 concentrations have not yet passed the 430 ppm mark in the Southern Hemisphere, which has a reversed cycle. It was Scripps scientist Charles David Keeling, father of Ralph Keeling, who was the first to recognise that CO2 levels in the Northern Hemisphere peaked in May. In 1958, he began monitoring CO2 concentrations at Mauna Loa Observatory and documented a long-term increase, known as the Keeling Curve. NOAA's Global Monitoring Laboratory, meanwhile, begun daily CO2 measurements in 1974 and has maintained a complementary, independent measurement record ever since.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
Aug 13 (Reuters) - Vaxart ( opens new tab said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech companies that have lost government funding for their vaccine programs. The drug developer said it will keep working on its oral COVID-19 vaccine by monitoring participants already in the trial, but it will stop new enrollment. The order is part of the U.S. Department of Health and Human Services decision to wind down mRNA vaccine development activities under its biomedical research unit. The unit, Biomedical Advanced Research and Development Authority, helps companies develop medical supplies to address public health threats, and had provided billions of dollars for development of vaccines during the COVID pandemic. This is the latest development under U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic who has been making sweeping changes to reshape vaccines, food and medicine policies. Kennedy said the HHS is terminating these programs because data show these vaccines "fail to protect effectively against upper respiratory infections like COVID and flu," but did not offer scientific evidence. Vaxart's project award was valued at up to $453 million, which included an upfront $65.7 million and up to $387.2 million in milestone payments. The milestone payment was dependent on whether BARDA determines that the study may further proceed.


Reuters
an hour ago
- Reuters
KBR secures NASA contract worth up to $3.6 billion for astronaut health support
Aug 13 (Reuters) - Engineering contractor KBR (KBR.N), opens new tab said on Wednesday it had secured a $2.46 billion contract from the National Aeronautics and Space Administration to support astronaut and worker health and safety during space missions. Shares of KBR rose 2.7% in extended trading. The five-year agreement, starting November 1, includes two optional extensions potentially extending the contract until 2035. Most work will be conducted at NASA's Johnson Space Center in Houston, Texas. The total estimated value, including the extensions, is $3.6 billion, the company said. The deal extends KBR's partnership with the space agency and underscores its role in spaceflight operations. KBR will provide services such as monitoring crew health, occupational health support and researching risk reduction strategies for astronauts, including those involved in the Artemis program aimed at future Moon missions. "This contract reinforces KBR's leadership in human spaceflight operations," said Mark Kavanaugh, KBR president, defense, intel and space.


Times
2 hours ago
- Times
Sam Altman and Elon Musk face off in race to link our brains with AI
The rivalry between two of the world's most powerful technology billionaires is moving into a new arena — the race to link human minds directly with machines. Sam Altman, chief executive of OpenAI, the company behind ChatGPT, was once an ally of Elon Musk, the Tesla and SpaceX boss. Now the former partners are preparing to face off in the fast-developing field of brain–computer interfaces (BCIs). These systems typically use artificial intelligence to translate brain activity into commands a computer can follow. They have enabled people with paralysis to control devices using only their thoughts. Advocates believe BCIs will one day allow humans to merge with advanced AI. Musk's company, Neuralink, began testing its technology on patients in the US last year and recently gained approval for a trial in Britain, its first in Europe. Altman is now backing a rival, Merge Labs, which aims to harness recent advances in AI to make BCIs faster and more capable, according to the Financial Times. In 2015 the pair launched OpenAI together when Musk provided much of the capital to launch the venture. They fell out three years later when Musk quit the board after disputes over how it would operate. Since then, they have built competing AI empires while publicly trading barbs Musk attempted to block OpenAI's transformation from a non-profit entity to a profit-seeking business. BCIs are drawing interest from governments as well as tech moguls. In the UK, the Advanced Research and Invention Agency (Aria), a government body, is exploring their potential as part of a broader mission to fund science that could change the world. In China, the Ministry of Industry and Information Technology has unveiled its own BCI device, Neo, intended to restore hand movement in paralysed patients. Neuralink is widely seen as being at the forefront of the field. Its coin-sized implant is designed to sit inside a small opening in the skull, with flexible electrode 'threads' extending into the brain to monitor the electrical activity of cells. An AI system then decodes those signals into information that can be used to control external devices. The company is also developing a surgical robot to carry out the procedure. Last year it implanted a device in its first human volunteer, Noland Arbaugh, who was paralysed from the shoulders down in a diving accident. Using the implant, he was able to move a computer cursor and play video games, an experience he likened to 'using the force' in a nod to Star Wars. While striking, this was not the first demonstration of a mind-driven technology. In the early 2000s, American scientists showed that monkeys implanted with neural interfaces could control robotic limbs through their thoughts. Human trials since then have allowed paralysed people to send emails, make purchases online and operate robotic devices — all without physical movement. In some cases, BCIs have been used to send information back towards the brain — allowing, for instance, a paralysed person to regain a sense of touch through a robotic hand. Musk said he wanted to go much further, including restoring sight to the blind and enabling quadriplegics to regain 'full-body functionality' — goals many researchers say could be decades away, if they are achievable at all. His ultimate ambition is a mass-market 'general population device' linking human minds directly to powerful computers, allowing 'symbiosis with artificial intelligence'. One industry figure who has discussed the matter with Musk said he viewed this as necessary to prevent superhuman AI from running out of control. Altman seems to share a similar long-term vision. In a blog post this year he wrote that 'high-bandwidth brain–computer interfaces' were on the horizon. Neuralink, which was founded in 2016, recently raised $650 million in a deal that valued the company at $9 billion. Altman, who had previously invested in the company, now appears to be positioning Merge Labs to challenge it directly. According to the Financial Times, Merge Labs is seeking funding at a valuation of about $850 million, with OpenAI's ventures arm expected to provide a large portion of an initial $250 million round. Altman is expected to help launch the project alongside Alex Blania, who runs Worldcoin, an eyeball-scanning digital ID project also backed by the OpenAI chief Neuralink said last month that it had received regulatory and ethics approvals to begin its first clinical study in the UK. The GB-Prime trial will be run at University College London Hospitals and Newcastle upon Tyne Hospitals NHS Foundation Trust. It will test the company's BCI in people with severe paralysis. The trial will involve patients with conditions such as motor neurone disease, spinal cord injuries and other neurological disorders, assessing whether they can use the device to control computers and other digital systems by thought alone.